Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) has strengthened its management team, appointing Helge Weiner-Trapness as its new chief strategy officer and executive director.
The newly created role will support the company’s long-term international growth strategy. His responsibilities include corporate development, partnership strategy, and portfolio prioritisation.
Also, the company has hired Lawrence Allen Wang as independent non-executive director. Wang is currently CFO of Adicon Clinical Laboratories, a clinical laboratory service provider in China, and he has previously held roles at Vivo Capital, Primavera Capital, Macquarie Group, and Goldman Sachs.
"I am pleased to welcome Helge and Larry to Allergy Therapeutics. Both bring deep investment and healthcare expertise that will be instrumental as the company pursues its long-term growth ambitions, including evaluating a potential dual listing on the Hong Kong Stock Exchange," chair Peter Jensen said.
Weiner-Trapness has more than 30 years of experience at global investment banks in the US and Asia. He was most recently Vice Chairman of Global Banking at HSBC Holdings plc. He also co-founded Quintus Partners, a Hong Kong-based advisory firm, and held senior roles at Barclays, Asia Pacific Land, J.P. Morgan Securities, and Goldman Sachs.
“Allergy Therapeutics has established a leading position in its core markets, with a significant portfolio and an innovative pipeline that present a strong platform for future growth. I am looking forward to working with the board and management team to drive the company's long-term strategy and international development, prioritising opportunities and executing a global strategy in a disciplined and sustainable way,” Weiner-Trapness said.
Wang, meanwhile, added: “Allergy Therapeutics has built a strong clinical and commercial platform, and I look forward to supporting the Board as the Company continues to develop its international strategy to become a global leader in allergy treatments.”